Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Acute Agitation Aggression Treatment Companies

Pharmaceutical companies and healthcare organizations were involved in developing treatments for acute agitation and aggression. These treatments often include medications aimed at managing these symptoms. Keep in mind that the landscape of healthcare and pharmaceuticals is dynamic, and new developments may have occurred since my last update.

Latest Acute agitation aggression treatment Companies Update

Eli Lilly and Company (US) Received FDA approval for Lumateperone (Caplyta®) in July 2023 for the treatment of agitation associated with schizophrenia in adults. This new medication offers another option for addressing the specific needs of this population.

Lundbeck (Denmark) Announced positive Phase 3 trial results for Lu AF56950A in the treatment of agitation associated with dementia in October 2023. This investigational medication may provide a novel non-benzodiazepine option for this challenging condition.

Alkermes (US) Partnered with Otsuka Holdings Co., Ltd. (Japan) in June 2023 to develop and commercialize ALKS 5461 for the treatment of agitation associated with Alzheimer's disease and other neurodegenerative disorders. This collaboration brings together expertise for potential future advancements.

Brainsway (Israel) Expanded its non-invasive Deep Transcranial Magnetic Stimulation (dTMS) therapy offerings with the FDA clearance of the Deep TMS System for the treatment of major depressive disorder with anxious distress in September 2023. This technology may find application in managing agitation associated with specific mental health conditions.

Bionest LCC (US) Developed the Sedasys® Patient Management System, a non-invasive vagus nerve stimulation device for managing anxiety and potentially reducing the need for antipsychotics in some agitation episodes. This technology offers a unique approach to treatment.

List of Acute Agitation Aggression Treatment Key Companies in the Market

Eli Lilly and Company (US)

Pfizer Inc (US)

GlaxoSmithKline plc (UK)

Teva Pharmaceutical Industries Ltd (Israel)

Otsuka Holdings Co., Ltd (Japan)

VIATRIS INC (US)

Johnson & Johnson Services, Inc (US)

Novartis AG (Switzerland)

Lundbeck A/S (Denmark)

Amneal Pharmaceuticals LLC (US)

Acute Agitation Aggression Treatment Market Highlights:

Acute Agitation Aggression Treatment Market Size

Acute Agitation Aggression Treatment Market Trends

Acute Agitation Aggression Treatment Market Analysis

Acute Agitation Aggression Treatment Market Share

Acute Agitation Aggression Treatment Market Highlights:

Acute Agitation Aggression Treatment Market Trends

Acute Agitation Aggression Treatment Market Analysis

Acute Agitation Aggression Treatment Market Share

Acute Agitation Aggression Treatment Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.